Cart is empty A Stanford Medicine-led, international study of hundreds of samples from patients with Hodgkin lymphoma has shown that levels of tumor DNA circulating in their blood can identify who is responding well to treatment and others who are likely to experience a disease recurrence—potentially letting some patients who are predicted to have favorable outcomes forgo lengthy treatment.
Leave A Comment